Jonathan R. Isaacson, MD
(Credit: LinkedIn)
A groundbreaking study has demonstrated that the Syn-One Test, developed by CND Life Sciences, is highly beneficial in diagnosing and treating patients with suspected synucleinopathies such as Parkinson’s disease (PD), multiple system atrophy (MSA), and Lewy body dementia (DLB). Published in Frontiers in Neurology, the findings underscore the vital role of this diagnostic tool in clinical decision-making and patient care.
The Syn-One Test and Its Impact
The Syn-One Test uses skin biopsy samples to detect phosphorylated α-synuclein, an abnormal protein associated with synucleinopathies. The study, which reviewed 97 patients at a tertiary care academic institution, found that the test significantly altered clinical care in 78% of cases. Specifically, 66% of patients experienced diagnostic changes, and 55% had treatment modifications, regardless of whether their biopsy results were positive or negative.
Diagnostic changes were particularly pronounced among patients exhibiting specific symptoms. For instance, 93% of patients with parkinsonism and prominent action tremor, 90% with postural instability and gait difficulties, and 76% with parkinsonism and significant cognitive dysfunction showed improved diagnoses. These findings emphasize the test’s utility in differentiating these complex conditions.
Methodology and Limitations
Investigators conducted a retrospective chart review of patients who underwent the Syn-One Test. The study included 54 patients with PD, 19 with DLB, and 24 with MSA. The goal was to evaluate how the detection of phosphorylated α-synuclein influenced clinical diagnoses and medical management.
Several limitations were noted, including the study’s retrospective design and small sample size, which may introduce bias. The use of chart reviews also limited detailed clinical follow-ups. Additionally, the study did not compare it with other diagnostic methods like biofluid tests or imaging. The findings from this large academic center may not be fully applicable to broader patient populations.
Expert Opinions
“Our study highlights the significant impact of skin biopsy for α-synuclein detection in improving clinical decision-making and patient care,” commented Roy Freeman, MD, professor of neurology and director of the Center for Autonomic and Peripheral Nerve Disorders at BIDMC. “This evidence supports the use of the Syn-One Test as a valuable diagnostic tool in community settings to evaluate patients with suspected synucleinopathies and guide them to specialized care when necessary.”
Sameea Husain-Wilson, DO, director of movement disorder neurology at the Marcus Neuroscience Institute of Baptist Health, echoed Freeman’s sentiments. In a recent interview with NeurologyLive®, she emphasized the test’s ability to quantify α-synuclein, crucial for accurate diagnosis and treatment among movement disorder specialists.
Conclusion
The Syn-One Test represents a significant advancement in the diagnosis and management of synucleinopathies. By providing a non-invasive and reliable method for detecting phosphorylated α-synuclein, the test can lead to more accurate diagnoses and targeted treatment plans, ultimately enhancing patient outcomes.
As the medical community continues to explore innovative diagnostic tools, the Syn-One Test’s clinical utility offers promising potential for improving the care of patients with Parkinson’s disease, multiple system atrophy, and Lewy body dementia.
